Pfizer argues for regulatory coherence with orphans, like tafamidis
This article was originally published in Scrip
In responding to the rejection on 25 January by English health ministers its one of its rare disease drugs, Vyndaqel, Pfizer took a side-swipe at the discrepancies between national and EU-level drug regulators, before insisting that it would continue to trying to get the drug to market in the UK.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.